Merck & Company (MRK) 60.58 $MRK
Research and Markets: Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry
Business Wire - 1 hr 43 mins ago
Research and Markets (http://www.researchandmarkets.com/research/b9xlc3/global) has announced the addition of the "Global Pneumococcal Vaccines Market 2014-2018" report to their offering.
Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry
M2 - 1 hr 43 mins ago
Research and Markets (http://www.researchandmarkets.com/research/2276th/global) has announced the addition of the "Global Pneumococcal Vaccines Market 2014-2018" report to their offering. The Global Pneumococcal Vaccines market to grow at a CAGR of 4.9% over the period 2013-2018 Pneumococcus (Streptococcus pneumonia), a pathogenic bacterium, is the leading cause of serious illness across the globe. It is the main cause of pneumonia, sinusitis, blood infections, meningitis, and middle ear infections (otitis media). Pneumococcal disease affects children and the elderly, and it is one of the leading infectious diseases worldwide. It kills almost 1.6 million people (including more than 800,000 children under the age five years) every year. Pneumococcal disease can be prevented by vaccination. Vaccination involves the introduction of dead or weakened antigen into the human body, which in turn produces lymphocytes to counter the infection and any future invasions by that antigen. One of the emerging trends in this market is strategic alliances of vendors in the market, resulting in consolidation. Such alliances are intended to increase the market penetration of the acquirer or to enhance the product portfolio of the parent company. According to the report, the major driving force in the market is the inclusion of the pneumococcal vaccination in the national immunization schedule of many countries, which helps to increase the consumption of vaccines in the market, thereby boosting growth. Further, the report states that the inadequate vaccine coverage in the world is a major challenge to the market growth, resulting in low reach of the vaccines in the market, which restrains growth. Key Vendors - GlaxoSmithKline - Merck - Pfizer Other Prominent Vendors - Lupin - Sanofi Pasteur MSD - S K Chemicals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Type - Market Assessment of Top Pneumococcal Vaccines - Geographical Segmentation - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/2276th/global
SIGMA-ALDRICH INVESTOR ALERT: Levi & Korsinsky, LLP Investigates the Board of Directors of Sigma-Aldrich Corporation In Connection with the Sale of the Company to Merck -- SIAL
PR Newswire - Mon Sep 22, 7:28PM CDT
Levi & Korsinsky is investigating the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or "the Company"
(NasdaqGS: SIAL) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to German drug company Merck.
Harwood Feffer LLP Announces Investigation of Sigma-Aldrich Corporation
PR Newswire - Mon Sep 22, 6:40PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company" (NASDAQ: SIAL) concerning the proposed acquisition of the Company by Merck KGaA ("Merck" .
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Sigma-Aldrich Corporation And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Sep 22, 4:08PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company" (NASDAQ: SIAL) relating to the proposed buyout of the Company by Merck KGaA ("Merck" , in a transaction valued at approximately $17 billion.
Stock Market Today: Stocks End Lower but Top Not Yet In Sight, Analysts Say
at The Street - Mon Sep 22, 3:24PM CDT
U.S. stocks close lower on Monday while strategists say the slide is just a temporary blip and predict the market still has more legs.
Surprising Silver Lining for Gilead Sciences, inc. Stock
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 22, 2:37PM CDT
Shares of Gilead Sciences got knocked down last week after CVS Health released data showing higher discontinuation rates for hepatitis C patients taking Sovaldi than Gilead Sciences saw in its clinical trials. Source: Gilead Sciences ...
Why Jim Cramer Says Dresser-Rand (DRC), Sigma-Aldrich (SIAL), TRW (TRW) Acquisitions Are Important
at The Street - Mon Sep 22, 12:16PM CDT
TheStreet's Jim Cramer explains why German companies' acquisitions of Dresser-Rand (DRC), Sigma-Aldrich (SIAL) and TRW (TRW) are so important.
SIGMA-ALDRICH INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Sigma-Aldrich Corp. Over the Proposed Sale of the Company to Merck KGaA - SIAL
PR Newswire - Mon Sep 22, 12:08PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Sigma-Aldrich Corp. ("Sigma-Aldrich" or the "Company" (Nasdaq: SIAL) for potential breaches of fiduciary duties in connection with the sale of the Company to Merck KGaA ("Merck" for approximately $17 billion. The Company's stockholders will receive $140 for each share of Sigma-Aldrich common stock they own.
Stock Market Today: Stocks Fall as China Dampens Stimulus Hopes
at The Street - Mon Sep 22, 11:37AM CDT
U.S. stock markets are down in trading early Monday afternoon after China signals it would not boost stimulus.
Sigma-Aldrich Hits High On Sale To Germany's Merck
at Investor's Business Daily - Mon Sep 22, 10:30AM CDT
Shares of Sigma-Aldrich (SIAL), a major provider of chemicals and other products for the life-science industry, jumped more than 34% to an all-time high near 138 in the stock market today after German drugmaker Merck KGaA announced it's buying the...
Why Sigma-Aldrich (SIAL) Stock Is Spiking Today
at The Street - Mon Sep 22, 10:09AM CDT
Sigma-Aldrich (SIAL) announced today that it agreed to be bought by Merck (MRK) for $17 billion.
Market Watchers Get a Breather - Ahead of Wall Street
Sheraz Mian - Zacks Investment Research - Mon Sep 22, 9:03AM CDT
Today's focus seems primarily on China, though next week will bring a host of top-tier Fed-centric data.
Merck to Expand Life Sciences With $17B Deal for Sigma-Aldrich
at The Street - Mon Sep 22, 8:52AM CDT
Germany's Merck on Monday claimed to have made a "quantum leap" in its life sciences business after striking a $17 billion deal to buy Sigma-Aldrich of St Louis.
Block & Leviton LLP Investigates Sigma-Aldrich Corporation for Possible Breaches of Fiduciary Duty in Connection with Its Merger with Merck KGaA
PR Newswire - Mon Sep 22, 8:51AM CDT
Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company" (NASDAQ: SIAL) concerning its proposed merger with Merck KGaA ("Merck" .
German Merck to buy St. Louis-based Sigma-Aldrich
By DAVID McHUGH - AP - Mon Sep 22, 8:03AM CDT
FRANKFURT, Germany (AP) — German drug company Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion in a deal Merck says will strengthen its business in chemicals and laboratory equipment.
Stock Market Today: Stock Futures Slip Amid Gloomy Global Mood
at The Street - Mon Sep 22, 7:50AM CDT
U.S. stock index futures are pointing to a softer start on Wall Street Monday, dragged down by the overall gloomy mood of the global markets.
Global Cattle Health Market 2014-2019 - Products, Cattle Diagnostics, Cattle Genetics, & Geography
M2 - Mon Sep 22, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zhg38/global_cattle) has announced the addition of the "Global Cattle Health Market - Segmented By Products, Cattle Diagnostics, Cattle Genetics, & Geography - Trends & Forecasts 2014-2019" report to their offering. The global market for cattle healthcare products and services is valued at $1.59 billion in 2014, and is expected to grow at a CAGR of 4.6 % to reach $2.02 billion by 2019 Cattle producers have long recognized the need for proper husbandry and stewardship, given the intensive animal husbandry model that currently houses a majority of cattle reared each year. Growing beef production and increasing demand for animal protein in an era of ever stricter regulations for rearing and food safety testing will have a positive impact on the cattle healthcare market. Major players are looking at the entire cattle healthcare ecosystem to maximize value for farmers. Creating value in addition to the products and services that firms offer has been a key strategy. The E=P S program, for instance, helps farmers become profitable while keeping their operations sustainable given more discriminating preferences of end-consumers. In this report, the market is segmented by type of disease into vaccines, Paraciticides, Anti-Infectives, Medicinal feed additives, and other pharmaceuticals. The market is further segmented by diagnostics -Enzyme Linked Sorbent Assay (ELISA), Rapid Immuno migration (RIM), and Agar Gel Immuno diffusion (AGID), and genetics. Regional markets analyzed in this report are North America, Europe, Asia-Pacific and the rest of the world (RoW). Pfizer (U.S.), Merck (U.S.), Sanofi-Aventis (France), Bayer HealthCare (Germany), Virbac (France), Novartis (Switzerland), Boehringer Ingelheim (Germany), Heska Corporation (U.S.), Bioniche Animal Health Canada, Inc. (Canada), and Ceva (France) are the key players in the global cattle healthcare market Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global Cattle Healthcare Market Segmentation 5. Competitive landscape 6. Company profiles For more information visit http://www.researchandmarkets.com/research/3z...bal_cattle
Research and Markets: Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry
Business Wire - 1 hr 43 mins ago
Research and Markets (http://www.researchandmarkets.com/research/b9xlc3/global) has announced the addition of the "Global Pneumococcal Vaccines Market 2014-2018" report to their offering.
Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry
M2 - 1 hr 43 mins ago
Research and Markets (http://www.researchandmarkets.com/research/2276th/global) has announced the addition of the "Global Pneumococcal Vaccines Market 2014-2018" report to their offering. The Global Pneumococcal Vaccines market to grow at a CAGR of 4.9% over the period 2013-2018 Pneumococcus (Streptococcus pneumonia), a pathogenic bacterium, is the leading cause of serious illness across the globe. It is the main cause of pneumonia, sinusitis, blood infections, meningitis, and middle ear infections (otitis media). Pneumococcal disease affects children and the elderly, and it is one of the leading infectious diseases worldwide. It kills almost 1.6 million people (including more than 800,000 children under the age five years) every year. Pneumococcal disease can be prevented by vaccination. Vaccination involves the introduction of dead or weakened antigen into the human body, which in turn produces lymphocytes to counter the infection and any future invasions by that antigen. One of the emerging trends in this market is strategic alliances of vendors in the market, resulting in consolidation. Such alliances are intended to increase the market penetration of the acquirer or to enhance the product portfolio of the parent company. According to the report, the major driving force in the market is the inclusion of the pneumococcal vaccination in the national immunization schedule of many countries, which helps to increase the consumption of vaccines in the market, thereby boosting growth. Further, the report states that the inadequate vaccine coverage in the world is a major challenge to the market growth, resulting in low reach of the vaccines in the market, which restrains growth. Key Vendors - GlaxoSmithKline - Merck - Pfizer Other Prominent Vendors - Lupin - Sanofi Pasteur MSD - S K Chemicals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Type - Market Assessment of Top Pneumococcal Vaccines - Geographical Segmentation - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/2276th/global
SIGMA-ALDRICH INVESTOR ALERT: Levi & Korsinsky, LLP Investigates the Board of Directors of Sigma-Aldrich Corporation In Connection with the Sale of the Company to Merck -- SIAL
PR Newswire - Mon Sep 22, 7:28PM CDT
Levi & Korsinsky is investigating the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or "the Company"
(NasdaqGS: SIAL) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to German drug company Merck. Harwood Feffer LLP Announces Investigation of Sigma-Aldrich Corporation
PR Newswire - Mon Sep 22, 6:40PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company"
(NASDAQ: SIAL) concerning the proposed acquisition of the Company by Merck KGaA ("Merck" . SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Sigma-Aldrich Corporation And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Sep 22, 4:08PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company"
(NASDAQ: SIAL) relating to the proposed buyout of the Company by Merck KGaA ("Merck" , in a transaction valued at approximately $17 billion. Stock Market Today: Stocks End Lower but Top Not Yet In Sight, Analysts Say
at The Street - Mon Sep 22, 3:24PM CDT
U.S. stocks close lower on Monday while strategists say the slide is just a temporary blip and predict the market still has more legs.
Surprising Silver Lining for Gilead Sciences, inc. Stock
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 22, 2:37PM CDT
Shares of Gilead Sciences got knocked down last week after CVS Health released data showing higher discontinuation rates for hepatitis C patients taking Sovaldi than Gilead Sciences saw in its clinical trials. Source: Gilead Sciences ...
Why Jim Cramer Says Dresser-Rand (DRC), Sigma-Aldrich (SIAL), TRW (TRW) Acquisitions Are Important
at The Street - Mon Sep 22, 12:16PM CDT
TheStreet's Jim Cramer explains why German companies' acquisitions of Dresser-Rand (DRC), Sigma-Aldrich (SIAL) and TRW (TRW) are so important.
SIGMA-ALDRICH INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Sigma-Aldrich Corp. Over the Proposed Sale of the Company to Merck KGaA - SIAL
PR Newswire - Mon Sep 22, 12:08PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Sigma-Aldrich Corp. ("Sigma-Aldrich" or the "Company"
(Nasdaq: SIAL) for potential breaches of fiduciary duties in connection with the sale of the Company to Merck KGaA ("Merck" for approximately $17 billion. The Company's stockholders will receive $140 for each share of Sigma-Aldrich common stock they own. Stock Market Today: Stocks Fall as China Dampens Stimulus Hopes
at The Street - Mon Sep 22, 11:37AM CDT
U.S. stock markets are down in trading early Monday afternoon after China signals it would not boost stimulus.
Sigma-Aldrich Hits High On Sale To Germany's Merck
at Investor's Business Daily - Mon Sep 22, 10:30AM CDT
Shares of Sigma-Aldrich (SIAL), a major provider of chemicals and other products for the life-science industry, jumped more than 34% to an all-time high near 138 in the stock market today after German drugmaker Merck KGaA announced it's buying the...
Why Sigma-Aldrich (SIAL) Stock Is Spiking Today
at The Street - Mon Sep 22, 10:09AM CDT
Sigma-Aldrich (SIAL) announced today that it agreed to be bought by Merck (MRK) for $17 billion.
Market Watchers Get a Breather - Ahead of Wall Street
Sheraz Mian - Zacks Investment Research - Mon Sep 22, 9:03AM CDT
Today's focus seems primarily on China, though next week will bring a host of top-tier Fed-centric data.
Merck to Expand Life Sciences With $17B Deal for Sigma-Aldrich
at The Street - Mon Sep 22, 8:52AM CDT
Germany's Merck on Monday claimed to have made a "quantum leap" in its life sciences business after striking a $17 billion deal to buy Sigma-Aldrich of St Louis.
Block & Leviton LLP Investigates Sigma-Aldrich Corporation for Possible Breaches of Fiduciary Duty in Connection with Its Merger with Merck KGaA
PR Newswire - Mon Sep 22, 8:51AM CDT
Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company"
(NASDAQ: SIAL) concerning its proposed merger with Merck KGaA ("Merck" . German Merck to buy St. Louis-based Sigma-Aldrich
By DAVID McHUGH - AP - Mon Sep 22, 8:03AM CDT
FRANKFURT, Germany (AP) — German drug company Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion in a deal Merck says will strengthen its business in chemicals and laboratory equipment.
Stock Market Today: Stock Futures Slip Amid Gloomy Global Mood
at The Street - Mon Sep 22, 7:50AM CDT
U.S. stock index futures are pointing to a softer start on Wall Street Monday, dragged down by the overall gloomy mood of the global markets.
Global Cattle Health Market 2014-2019 - Products, Cattle Diagnostics, Cattle Genetics, & Geography
M2 - Mon Sep 22, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zhg38/global_cattle) has announced the addition of the "Global Cattle Health Market - Segmented By Products, Cattle Diagnostics, Cattle Genetics, & Geography - Trends & Forecasts 2014-2019" report to their offering. The global market for cattle healthcare products and services is valued at $1.59 billion in 2014, and is expected to grow at a CAGR of 4.6 % to reach $2.02 billion by 2019 Cattle producers have long recognized the need for proper husbandry and stewardship, given the intensive animal husbandry model that currently houses a majority of cattle reared each year. Growing beef production and increasing demand for animal protein in an era of ever stricter regulations for rearing and food safety testing will have a positive impact on the cattle healthcare market. Major players are looking at the entire cattle healthcare ecosystem to maximize value for farmers. Creating value in addition to the products and services that firms offer has been a key strategy. The E=P S program, for instance, helps farmers become profitable while keeping their operations sustainable given more discriminating preferences of end-consumers. In this report, the market is segmented by type of disease into vaccines, Paraciticides, Anti-Infectives, Medicinal feed additives, and other pharmaceuticals. The market is further segmented by diagnostics -Enzyme Linked Sorbent Assay (ELISA), Rapid Immuno migration (RIM), and Agar Gel Immuno diffusion (AGID), and genetics. Regional markets analyzed in this report are North America, Europe, Asia-Pacific and the rest of the world (RoW). Pfizer (U.S.), Merck (U.S.), Sanofi-Aventis (France), Bayer HealthCare (Germany), Virbac (France), Novartis (Switzerland), Boehringer Ingelheim (Germany), Heska Corporation (U.S.), Bioniche Animal Health Canada, Inc. (Canada), and Ceva (France) are the key players in the global cattle healthcare market Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Global Cattle Healthcare Market Segmentation 5. Competitive landscape 6. Company profiles For more information visit http://www.researchandmarkets.com/research/3z...bal_cattle
